⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Ticagrelor

تیکاگرلور

⚠ Unverified

🩸 Blood And Blood Forming OrgansP2Y12 inhibitor (antiplatelet)

🤰 Pregnancy:Use with caution 🤱 Breastfeeding:Dangerous / avoid 👶 Children:Use with caution 👴 Older adults:No specific problem stated 🇮🇷 Registered in Iran ⛔ 1 contraindications 🇺🇸 FDA approved (NDA) NDA022433 ATC B01AC24

Market / country: 🇺🇸 USA

Brilinta (US)

🧮 Dose calculator

Disease / regimen

Acute coronary syndrome / post-MI · Regimen source: FDA Brilinta · 2.2

Formulation

Age *

Weight (kg) (optional)

Enter age (weight is optional for this regimen).

🛡️ Safety & information

Contraindications

⛔ History of intracranial haemorrhage; active pathological bleeding; hypersensitivity. FDA Brilinta · 4

Warnings

• Boxed warning: significant, sometimes fatal bleeding; do not start before urgent CABG; premature discontinuation increases cardiovascular events. FDA Brilinta · Boxed Warning

Formulations

60 mg tablet — tablet 🇺🇸 USA FDA Brilinta · 3
90 mg tablet — tablet 🇺🇸 USA FDA Brilinta · 3

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Brilinta · 8.1
“Risk Summary Available data from case reports with BRILINTA use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.”
🤱 BreastfeedingDangerous / avoid
Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Brilinta · 8.2
“Breastfeeding is not recommended during treatment with BRILINTA.”
👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Brilinta · 8.4
“The safety and effectiveness of BRILINTA have not been established in pediatric patients.”
👴 Older adultsNo specific problem stated
Label: no specific difference or dose adjustment stated for older adults. FDA Brilinta · 8.5
“No overall differences in safety or effectiveness were observed between elderly and younger patients.”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)NDA022433
DailyMed (FDA label)FDA Brilinta
MedlinePlus (NIH)Ticagrelor
WHO ATC/DDDB01AC24
Darooyab (Iran)Ticagrelor

🇮🇷 Registered in Iran Darooyab · G-4697/Ticagrelor

Dosage forms with Iranian generic codes, per Darooyab.

18002 · TICAGRELOR 90 MG TAB. · قرص تیکاگرلور ۹۰ میلی‌گرم .
52087 · TICAGRELOR 60 MG TAB · قرص تیکاگرلور ۶۰ میلی‌گرم

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Brilinta · 3 FDA Brilinta · 2.2 FDA Brilinta · 2.1 FDA Brilinta · 2.3 FDA Brilinta · 2.4 FDA Brilinta · 4 FDA Brilinta · Boxed Warning FDA Brilinta · 8.1 FDA Brilinta · 8.2 FDA Brilinta · 8.4 FDA Brilinta · 8.5 FDA Brilinta · SPL approval / marketing category
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · G-4697/Ticagrelor
Clinical review⚠ Unverified

🔗 Similar drugs

Same class

Clopidogrel

For the same diseases

Aspirin (acetylsalicylic acid)Carvedilol Lisinopril Metoprolol tartrate Ramipril